| The COVID-19 vaccine development landscape #MMPMID32273591Thanh Le T; Andreadakis Z; Kumar A; Gomez Roman R; Tollefsen S; Saville M; Mayhew SNat Rev Drug Discov 2020[May]; 19 (5): 305-306 PMID32273591show ga
ä|*Betacoronavirus/immunology[MESH]|*Drug Development[MESH]|*Viral Vaccines/administration & dosage/chemistry/genetics/immunology[MESH]|Aged[MESH]|COVID-19[MESH]|COVID-19 Vaccines[MESH]|Child[MESH]|Clinical Trials, Phase I as Topic[MESH]|Coronavirus Infections/genetics/immunology/*prevention & control/virology[MESH]|Drug Industry[MESH]|Female[MESH]|Genetic Vectors[MESH]|Humans[MESH]|Internationality[MESH]|Pandemics/*prevention & control[MESH]|Pneumonia, Viral/immunology/*prevention & control/virology[MESH]|Pregnancy[MESH]|SARS-CoV-2[MESH]|Time Factors[MESH]|Vaccines, Attenuated[MESH]|Vaccines, Inactivated[MESH]|Vaccines, Subunit[MESH]
DeepDyve Pubget Overpricing |
|